West Pharmaceutical Services, Inc. has increased its equity stake in Daikyo Seiko, Ltd. to 49 percent. West and Daikyo have partnered for more than 40 years to develop and manufacture high-quality components and solutions for the primary containment and delivery of injectable medicines.

The companies long-standing agreements include a distribution agreement, under which West distributes and markets Daikyo products globally, on an exclusive basis, as well as a technology exchange and cross license agreement, which grants each party certain exclusive intellectual property rights for the manufacture of products covered by the relationship. Additionally, Daikyo has distribution rights of West products in Japan.

“West and Daikyo have formed an exceptional, long-term partnership to supply critically important components for the containment and delivery of injectable medicines,” said Eric M. Green, president and chief executive officer, West. “At West, we value and admire the innovative products that Daikyo offers—they are an ideal complement to West’s portfolio of products and services. We look forward to our continued partnership and collaboration as we continue to work together to offer our customers the next generation of integrated packaging and delivery innovations.” 

“Daikyo specializes in improving product quality to the highest level possible—always seeking to develop innovative components and solutions that can lead us to absolute quality,” said Morihiro Sudo, president, Daikyo Seiko, Ltd. “We are proud to work with West, a company that shares this commitment, and look forward to our continued collaboration to deliver even more products to the market in the future.”